[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:x-linked-lymphoproliferative-syndrome-1":3},{"name":4,"total":5,"recruiting":6,"trials":7},"X-linked Lymphoproliferative Syndrome 1",36,29,[8,16,23,30,36,42,49,55,61,68,74,80,86,91,97,103,109,115,121,127,133,138,144,150,156,162,168,174,180,186,193,199,205,211,217,224],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06972069","Tolerance Through Mixed Chimerism (Sip-Tego)",[12],"Early Phase 1","RECRUITING","2026-08-26T02:19:06.150683Z","2026-07-24T01:27:14.896734Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT06056102","CAR-T Cell Therapy for Desensitization in Kidney Transplantation",[20],"Phase 1","2026-08-26T02:18:26.932189Z","2026-07-05T05:32:16.746896Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":28,"content_modified":29},"NCT06478017","Belatacept in Heart Transplantation",[27],"Phase 2","2026-08-26T02:16:05.813655Z","2026-05-05T02:47:14.272393Z",{"nct_id":31,"title":32,"phases":33,"status":13,"updated_at":34,"content_modified":35},"NCT06055608","Advancing Transplantation Outcomes in Children",[27],"2026-08-26T02:15:28.524219Z","2026-05-05T02:43:29.726122Z",{"nct_id":37,"title":38,"phases":39,"status":13,"updated_at":40,"content_modified":41},"NCT03258567","Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas",[27],"2026-08-26T02:16:35.654046Z","2026-05-05T02:43:29.390326Z",{"nct_id":43,"title":44,"phases":45,"status":13,"updated_at":47,"content_modified":48},"NCT04877288","A Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Kidney Transplant Recipients Aged 12 to \u003C18 Years to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive Medications",[46],"Phase 3","2026-08-26T02:17:49.709549Z","2026-05-05T02:43:29.362836Z",{"nct_id":50,"title":51,"phases":52,"status":13,"updated_at":53,"content_modified":54},"NCT06592599","Gemcitabine + Docetaxel + Toripalimab Induction in Epstein-Barr Virus (EBV) Associated Nasopharyngeal Carcinoma(NPC)",[27],"2026-08-26T02:15:13.282904Z","2026-05-05T02:43:28.486595Z",{"nct_id":56,"title":57,"phases":58,"status":13,"updated_at":59,"content_modified":60},"NCT06789159","A Phase Ib Study of VK-2019 in Patients With Relapsed or Refractory EBV+ Diffuse Large B-cell Lymphomas (DLBCL)",[20],"2026-08-26T02:17:18.747857Z","2026-05-05T02:43:28.339016Z",{"nct_id":62,"title":63,"phases":64,"status":13,"updated_at":66,"content_modified":67},"NCT07224763","Study to Evaluate the Safety and Efficacy of the GGTA1 KO Thymokidney in Patients With ESRD",[65],"Phase 1\u002FPhase 2","2026-08-26T02:14:59.425132Z","2026-05-05T02:43:28.114641Z",{"nct_id":69,"title":70,"phases":71,"status":13,"updated_at":72,"content_modified":73},"NCT06682442","Induction Chemotherapy Response-Guided Radiation for EBV-Associated Nasopharyngeal Carcinoma",[],"2026-08-26T02:15:02.712396Z","2026-05-05T02:43:27.927698Z",{"nct_id":75,"title":76,"phases":77,"status":13,"updated_at":78,"content_modified":79},"NCT05338658","Study of PAT in Patients With Solid Tumor Cancers",[20],"2026-08-26T02:17:22.153941Z","2026-05-05T02:43:27.915457Z",{"nct_id":81,"title":82,"phases":83,"status":13,"updated_at":84,"content_modified":85},"NCT06138132","A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis",[20],"2026-08-26T02:16:29.226604Z","2026-05-05T02:43:27.264594Z",{"nct_id":87,"title":88,"phases":89,"status":13,"updated_at":72,"content_modified":90},"NCT06455280","A Study of SIPLIZUMAB in AILD and LT Patients",[20],"2026-05-05T02:43:26.978311Z",{"nct_id":92,"title":93,"phases":94,"status":13,"updated_at":95,"content_modified":96},"NCT03394365","A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy",[46],"2026-08-26T02:19:11.399072Z","2026-05-05T02:43:26.675337Z",{"nct_id":98,"title":99,"phases":100,"status":13,"updated_at":101,"content_modified":102},"NCT06878560","Study to Evaluate the Safety and Efficacy of the 10 GE Xenokidney in Patients With ESRD",[65],"2026-08-26T02:16:50.548894Z","2026-05-05T02:35:31.909367Z",{"nct_id":104,"title":105,"phases":106,"status":13,"updated_at":107,"content_modified":108},"NCT06735248","A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years",[27],"2026-08-26T02:19:14.560989Z","2026-05-05T02:35:31.876029Z",{"nct_id":110,"title":111,"phases":112,"status":13,"updated_at":113,"content_modified":114},"NCT06305286","Safety, Tolerability, and Efficacy of Immunomodulation With A Monoclonal Antibody Against CD40L in Combination With Transplanted Islet Cells in Adults With Brittle Type 1 Diabetes Mellitus (T1D)",[65],"2026-08-03T03:49:37.452409Z","2026-04-29T02:57:57.154309Z",{"nct_id":116,"title":117,"phases":118,"status":13,"updated_at":119,"content_modified":120},"NCT01555892","Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE",[20],"2026-08-26T02:16:36.513735Z","2026-05-05T02:43:28.315377Z",{"nct_id":122,"title":123,"phases":124,"status":13,"updated_at":125,"content_modified":126},"NCT04664179","EBV Specific T-Lymphocytes for Treatment of EBV-Positive Lymphoma",[20],"2026-08-26T02:19:19.162260Z","2026-05-05T02:43:27.322391Z",{"nct_id":128,"title":129,"phases":130,"status":13,"updated_at":131,"content_modified":132},"NCT02579967","Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies",[27],"2026-08-26T02:19:04.543908Z","2026-05-05T02:43:27.958949Z",{"nct_id":134,"title":135,"phases":136,"status":13,"updated_at":34,"content_modified":137},"NCT05475925","A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas",[65],"2026-05-05T02:43:27.068416Z",{"nct_id":139,"title":140,"phases":141,"status":13,"updated_at":142,"content_modified":143},"NCT06834373","Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy",[27],"2026-08-26T02:16:14.341106Z","2026-05-05T02:43:26.687370Z",{"nct_id":145,"title":146,"phases":147,"status":13,"updated_at":148,"content_modified":149},"NCT04477629","Belatacept in De Novo Heart Transplantation",[27],"2026-08-26T02:17:33.807405Z","2026-05-05T02:43:29.199314Z",{"nct_id":151,"title":152,"phases":153,"status":13,"updated_at":154,"content_modified":155},"NCT07096453","CMVIG Prophylaxis in Belatacept Conversion Kidney Transplant Recipients",[65],"2026-08-26T02:16:08.402952Z","2026-05-05T02:43:27.595971Z",{"nct_id":157,"title":158,"phases":159,"status":13,"updated_at":160,"content_modified":161},"NCT06723457","Epcoritamab and Lenalidomide in Treating Patients With Refractory or Relapsed Immunodeficiency-Related Large B-Cell Lymphoma",[27],"2026-08-26T02:17:54.420226Z","2026-07-19T19:36:05.137870Z",{"nct_id":163,"title":164,"phases":165,"status":13,"updated_at":166,"content_modified":167},"NCT00032513","Genetic Studies of Chronic Active Epstein-Barr Disease",[],"2026-08-26T02:17:17.791881Z","2026-05-13T02:55:06.030356Z",{"nct_id":169,"title":170,"phases":171,"status":13,"updated_at":172,"content_modified":173},"NCT05663502","Collecting Blood and Tissue Sample Donations for Research for HIV\u002FAIDS-Related Cancers",[],"2026-08-26T02:15:45.413021Z","2026-05-13T02:55:06.369655Z",{"nct_id":175,"title":176,"phases":177,"status":13,"updated_at":178,"content_modified":179},"NCT00006518","Specimen Collections From Participants With HIV Infection, KSHV Infection, Viral-Related Pre-malignant Lesions and Cancer",[],"2026-08-26T02:17:21.315591Z","2026-05-13T02:55:06.028653Z",{"nct_id":181,"title":182,"phases":183,"status":13,"updated_at":184,"content_modified":185},"NCT04230356","Trial of Scheduled Versus Treatment Administration of Donor-Derived Viral Specific T-cells for Viral Infections After Stem Cell Transplant",[27],"2026-08-26T02:16:41.943926Z","2026-05-05T02:43:28.418059Z",{"nct_id":187,"title":188,"phases":189,"status":190,"updated_at":191,"content_modified":192},"NCT07650266","A Study of Cemiplimab and Fianlimab in People With Nasopharyngeal Carcinoma",[20],"NOT_YET_RECRUITING","2026-08-26T02:15:52.238965Z","2026-06-17T02:29:30.061545Z",{"nct_id":194,"title":195,"phases":196,"status":190,"updated_at":197,"content_modified":198},"NCT07204080","(TNX-1500) in Kidney Transplant Recipients",[27],"2026-08-26T02:19:29.922117Z","2026-05-05T02:43:29.704394Z",{"nct_id":200,"title":201,"phases":202,"status":190,"updated_at":203,"content_modified":204},"NCT07588698","Epcoritamab in Combination With R-CHOP for Patients With Aggressive Non-Hodgkin Lymphoma",[27],"2026-08-26T02:16:49.565137Z","2026-05-29T15:36:40.200627Z",{"nct_id":206,"title":207,"phases":208,"status":190,"updated_at":209,"content_modified":210},"NCT07720180","Study of Autologous, Metabolically Optimized, CD137+ Tumor-Infiltrating Lymphocytes Followed by Consolidative Oral Cyclophosphamide, Bevacizumab, and Pembrolizumab",[27],"2026-08-26T02:17:35.666428Z","2026-07-24T01:27:14.923141Z",{"nct_id":212,"title":213,"phases":214,"status":190,"updated_at":215,"content_modified":216},"NCT07696962","Study of ChoironeX GalKO Porcine Thymokidney Xenotransplantation in End-Stage Renal Disease",[20],"2026-08-26T02:18:19.586423Z","2026-07-19T19:36:05.078420Z",{"nct_id":218,"title":219,"phases":220,"status":221,"updated_at":222,"content_modified":223},"NCT05973734","Islet Transplantation With Recipient T-Reg Cells or Deceased Donor Vertebral Bone Marrow Therapy",[20],"ENROLLING_BY_INVITATION","2026-08-26T02:17:30.961790Z","2026-05-05T02:43:28.113172Z",{"nct_id":225,"title":226,"phases":227,"status":221,"updated_at":228,"content_modified":229},"NCT05957913","Effects of Antiviral Therapies on Epstein-Barr Virus Replication",[27],"2026-08-26T02:16:47.762107Z","2026-06-16T05:54:08.092801Z"]